Skip to main content
Premium Trial:

Request an Annual Quote

Drug Discovery Startup Engine Biosciences Raises $10M

NEW YORK (GenomeWeb) – Drug discovery startup Engine Biosciences announced today that it has raised $10 million in seed funding.

The oversubscribed round was co-led by Danhua Capital and 6 Dimensions Capital, and included WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest Bio Ventures.

Engine said it would use the funding to continue development of its drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence algorithms, as well as to expand its scientific and executive teams in Singapore and San Francisco. The company also aims to conduct preclinical studies internally and with partners.

"Engine's data-driven platform allows researchers to uncover the critical gene interactions underlying diseases and also test therapies that specifically target these interactions in a faster, cheaper, and more precise fashion than currently possible," Engine Cofounder and CEO Jeffrey Lu said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.